Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Neutropenia 1Hematologic Neoplasms 1

Interventions

Dexamethasone 242Lenalidomide 147daratumumab 125Bortezomib 102pomalidomide 88Calcium Dobesilate 76carfilzomib 75Cyclophosphamide 71Specimen Handling 42isatuximab 41Biopsy 40belantamab mafodotin 37fludarabine 36Magnetic Resonance Spectroscopy 35talquetamab 29Melphalan 28dexamethasone acetate 27dexamethasone 21-phosphate 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Loratadine × 1 year × Clear all
NCT04211259 2026-05-29

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma

NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡